EU MediPoint Coronary Stents Industry Analysis and Market Forecasts

download EU MediPoint Coronary Stents Industry Analysis and Market Forecasts

of 23

  • date post

    26-Dec-2015
  • Category

    Documents

  • view

    11
  • download

    0

Embed Size (px)

description

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

Transcript of EU MediPoint Coronary Stents Industry Analysis and Market Forecasts

  • MediPoint: Coronary Stents - Current and Future Players

    Market Research Store has published new research report titled MediPoint: Coronary Stents - Current and Future

    Players to their report store.

  • sales@marketresearchstore.com

    The global coronary stents market is a dynamic, double-digit market that is saturated

    with numerous players developing innovative technologies. Rapid advances in the field

    of interventional cardiology along with the development of minimally invasive

    techniques have greatly expanded the potential of therapeutic applications. Coronary

    stents including bare metal, drug-eluting, covered and bioabsorbable stents can be

    used to treat coronary artery disease, and optimize outcomes.

    The coronary stents market in the EU has an overall negative CAGR of 0.5% over the

    forecast period from 2011-2020. Similar to the US, the DES market in the EU has the

    largest share, where the DES market is four times that of the BMS market. Moving

    forward, GlobalData believes that the DES market will grow slowly due to the improved

    outcomes, the development of low-profile systems and the next generation of DES, and

    cost-savings due to the reduced need for repeat intervention.

    In the EU, there is a strong dependency on reimbursement, which can vary between

    nations. German reimbursement has generally been strong for medical devices, and

  • sales@marketresearchstore.com

    has been less of a problem. However, the other countries are keen to follow clinical

    outcomes carefully for adoption and product usage in order to obtain reimbursement.

    Scope

    An overview of Coronary Stents, which includes epidemiology, etiology,

    symptoms, diagnosis, pathology and treatment guidelines.

    Annualized EU Coronary Stents market revenue and future forecasts from 2011

    to 2013, forecast for 7 years to 2020.

    Investigation of current and future market competition for Coronary Stents.

    Insightful review of the key industry drivers, restraints and challenges as well as

    predicted impact of key events.

    Competitor assessment including device approval analysis and device sales

    forecasts.

    Marketed and pipeline product profiles covering efficiency, safety, clinical study

    details, device approvals, product positioning and device sales forecast.

    Analysis of unmet needs within the market and opportunities for future players.

    Technology trends evaluation to assess strength of pipeline.

  • sales@marketresearchstore.com

    An overview of all devices in development including clinical study details, design

    and material selection considerations, efficacy reports, and device approval

    timelines.

    Company profiles including business description, financial overview and SWOT

    analysis.

    Coverage of key market players.

    Strategic assessment of the Coronary Stents sector through market impact

    analysis, future market scenario and company analysis.

    Direct quotes from Key Opinion Leaders (KOL) as well as doctors

    For more details MediPoint: Coronary Stents - Current and Future Players

    report, please visit: http://www.marketresearchstore.com/report/medipoint-

    coronary-stents-eu-analysis-and-market-forecasts-1796

    Reasons to Buy

    DUnderstand the trends shaping and driving the EU Coronary Stents market.

    Realize device preferences of physicians who have performed the tests already.

  • sales@marketresearchstore.com

    Access market sizing, forecasts and quantified growth opportunities in the US

    Coronary Stents market through 2018.

    Quantify candidate patient populations to better design product pricing & launch

    plans.

    Drive revenues, formulate effective sales and marketing strategies and gain in-

    depth understanding of the competitive landscape.

    Perform benchmarking analysis of growth opportunities against currently

    marketed products.

    Assess competitiveness of products in market by understanding the strengths

    and weaknesses of current competition.

    Take a comprehensive look at the markets device pipeline and identify

    promising, paradigm-shifting products.

    Create an effective counter-strategy to gain a competitive advantage against

    those currently in the market.

    Organize your sales and marketing efforts by identifying the market categories

    and segments that present the best opportunities for growth.

  • sales@marketresearchstore.com

    Whats the next big thing in the EU Coronary Stents market landscape? Identify,

    understand and capitalize.

    1 Table of Contents

    1 Table of Contents 8

    1.1 List of Tables 16

    1.2 List of Figures 23

    Want to buy this report, click here:

    http://www.marketresearchstore.com/checkout/reportId/1796/reportType/0

    2 Introduction 25

    2.1 Catalyst 26

  • sales@marketresearchstore.com

    2.2 Related Reports 27

    3 Industry Overview 28

    3.1 Disease Overview 28

    3.2 Clinical Outcomes 29

    3.2.1 Treatment Guidelines 29

    3.2.2 Treatment Modalities 30

    3.3 Procedure Trends 44

    3.3.1 European Union 45

    3.4 Market Access 47

    3.4.1 Regulatory Process 48

    3.4.2 Physician Decision-Making Process 49

    3.4.3 Role of Group Purchasing Organizations 53

  • sales@marketresearchstore.com

    3.4.4 Lack of Clinical Data 56

    3.4.5 Regional-Level Control 58

    3.4.6 Cost Considerations 58

    3.4.7 Reimbursement Trends 59

    3.5 Regulatory Issues/Recalls 64

    3.5.1 Regulatory Issues 64

    3.5.2 Product Recalls 65

    3.6 Mergers and Acquisitions/ Key Partnerships 65

    3.6.1 Medtronic and Covidien 65

    3.6.2 Arterial Remodeling Technologies and Terumo Corporation 66

    3.6.3 MicroPort Scientific Corporation and Cordis Corporation 66

    3.6.4 Alvimedica and CID 67

    3.6.5 ITGI Medical and Vascular Solutions 67

  • sales@marketresearchstore.com

    3.6.6 Terumo Corporation and Onset Medical Corporation 67

    3.6.7 Atrium Medical and Getinge Group 68

    3.6.8 C.R. Bard and ClearStream Technologies 68

    3.6.9 Biosensors International and Devax, CardioMind, and JW Medical Systems 69

    3.6.10 CeloNova Biosciences and Nexeon MedSystems 70

    3.6.11 Medtronic and Invatec 70

    3.6.12 Micell Technologies and Maxcor Lifescience 71

    3.6.13 Boston Scientific Corporation and Guidant Corporation 71

    3.6.14 Abbott Vascular and Guidant Corporation 71

    3.6.15 Kaneka Corporation and Fujisawa Pharmaceuticals 72

    3.7 Economic Impact of Coronary Artery Disease 72

    3.7.1 European Union 73

    3.8 Treatment Costs for Coronary Artery Disease 74

  • sales@marketresearchstore.com

    4 Unmet Needs 76

    4.1 Need for Better Clinical Outcomes in Specific Lesions 76

    4.1.1 Chronic Total Occlusions 76

    4.1.2 Small-Vessel Coronary Lesions 77

    4.1.3 Heavily-Calcified and Uncrossable/Undilatable Lesions 78

    4.1.4 Bifurcation Lesions 78

    4.1.5 Saphenous Vein Graft Intervention 79

    4.2 Eliminating Mechanisms of Failure With Balloon Angioplasty 80

    4.3 Late Myocardial Infarction After Stenting 80

    4.4 Eliminating the Permanent Polymer 81

    4.5 In-Stent Restenosis 82

    4.6 Stent-In-Stent Procedures 84

  • sales@marketresearchstore.com

    4.7 Prolonged Dual Antiplatelet Therapy 85

    4.8 Lack of Homogenous Drug Distribution 86

    4.9 Delayed Stent Endothelialization 86

    4.10 Negative Vessel Remodeling 87

    4.11 Need for Effective Therapy for Specific Patient Populations 87

    4.12 Addressing the Complications of Coronary Artery Bypass Grafting 88

    5 Market Opportunity Analysis 89

    5.1 Improve Stent Design/Platform 89

    5.1.1 Stent Coating Technology 90

    5.1.2 Bioabsorbable Stent Technology 92

    5.1.3 Antiproliferative Drug and Elution Kinetics 93

    5.2 Hybrid Stent Systems 95

  • sales@marketresearchstore.com

    5.3 Effective Therapies for Challenging Coronary Indications 96

    5.3.1 Chronic Total Occlusions 96

    5.3.2 Small-Vessel Disease 96

    5.3.3 Bifurcation Lesions 97

    5.3.4 Diffuse Atherosclerotic Disease 98

    5.3.5 Saphenous Vein Graft Intervention 98

    5.3.6 Acute Myocardial Infarction 98

    5.4 Target Challenging Patient Populations 99

    5.5 Emerging Markets 100

    6 Market Drivers, Barriers, and Substitutes 101

    6.1 Market Drivers 101

    6.1.1 Rising Prevalence of Disease 102

  • sales@marketresearchstore.com

    6.1.2 Viable Treatment for Challenging Coronary Indications 103

    6.1.3 Innovations in Stent Technology 104

    6.1.4 Development of Bioabsorbable Stents 106

    6.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 108

    6.1.6 Potential Cost Savings 109

    6.1.7 Use of Imaging Modalities for Accurate Stent Placement 110

    6.1.8 Adoption of Stents in the Emerging Markets 110

    6.1.9 Launch of Bioabsorbable Stents in US and Japan 111

    6.2 Market Barriers 111

    6.2.1 Concerns Regarding Overstenting 111

    6.2.2 Post-ProceduraI Complications of Drug-Eluting Stenting 112

    6.2.3 Risk of Perioperative Adverse Cardiac Events Post-Stenting 112

    6.2.4 Slow Adoption of Bioabsorbable Stents 113

  • sales@marketresearchstore.com

    6.2.5 Lack of Reimbursement 118

    6.2.6 Healthcare Cost-Cutting and Reimbursement 119

    6.2.7 Availability of Venture Capital 120

    6.2.8 Medical Device Excise Tax 1